Verona Pharma plc (NASDAQ:VRNA) Given Consensus Rating of

Dec 17, 2024 · Verona Pharma plc (NASDAQ:VRNA - Get Free Report) has been assigned a consensus rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 …

$0.56
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus

2 weeks from now

4 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Monday, November 4th.The company reported ($0.56) earnings per share …

marketbeat.com

5%
OFF

Verona Pharma (NASDAQ:VRNA) Stock Price Up 4.5% - MarketBeat

2 weeks from now

2 days ago · Shares of Verona Pharma plc ... Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from …

marketbeat.com

$42
OFF

Verona Pharma (NASDAQ:VRNA) Stock, Analyst Ratings, Price …

2 weeks from now

Jan 1, 2019 · Verona Pharma PLC has a consensus price target of $42 based on the ratings of 7 analysts. The high is $64 issued by Wells Fargo on November 5, 2024 . The low is $31 issued …

benzinga.com

04%
OFF

Verona Pharma Plc (VRNA) Analyst Ratings - Stock Analysis

2 weeks from now

Dec 12, 2024 · Verona Pharma plc (VRNA) NASDAQ: VRNA · Real-Time Price · USD. Watchlist Compare. 42.68 +1.26 (3.04%) Dec 16, 2024, 4:00 PM EST - Market closed ... Analyst …

stockanalysis.com

$37.00
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus ... - Defense …

2 weeks from now

4 days ago · VRNA has been the topic of several analyst reports. Canaccord Genuity Group raised their price target on shares of Verona Pharma from $37.00 to $44.00 and gave the …

defenseworld.net

$37.00
OFF

Buy Rating Affirmed For Verona Pharma: Breakthrough COPD …

2 weeks from now

Aug 14, 2024 · Canaccord Genuity analyst Edward Nash maintained a Buy rating on Verona Pharma (VRNA – Research Report) yesterday and set a price target of $37.00.. Edward Nash …

businessinsider.com

$74.00
OFF

Verona Pharma (NASDAQ:VRNA) Price Target Raised To $74.00

2 weeks from now

4 days ago · Finally, Canaccord Genuity Group increased their price target on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research report on Tuesday, …

etfdailynews.com

$35.00
OFF

Strategic Financing Secures Verona Pharma’s Future Beyond 2026 ...

2 weeks from now

May 13, 2024 · In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $35.00. …

businessinsider.com

$45.20
OFF

Verona Pharma (NASDAQ:VRNA) Upgraded By Roth Capital To …

2 weeks from now

2 days ago · NASDAQ:VRNA opened at $45.20 on Friday. The stock has a 50-day moving average price of $41.33 and a 200 day moving average price of $31.64. The stock has a …

etfdailynews.com

65%
OFF

Wall Street Analysts See A 30.65% Upside In Verona Pharma

2 weeks from now

14 hours ago · Verona Pharma PLC American Depositary Share (VRNA) closed the last trading session at $46.69, gaining 9.4% over the past four weeks, but there could be plenty of upside …

nasdaq.com

$44.44
OFF

Verona Pharma (NASDAQ:VRNA) Sets New 1-Year High - Here's …

2 weeks from now

Dec 23, 2024 · Verona Pharma plc (NASDAQ:VRNA - Get Free Report)'s share price hit a new 52-week high on Monday . The company traded as high as $44.44 and last traded at $43.47, …

marketbeat.com

$0.56
OFF

Verona Pharma (NASDAQ:VRNA) Earns "Buy" Rating From Truist

2 weeks from now

6 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th.The company reported ($0.56) EPS for the …

marketbeat.com

$0.56
OFF

Verona Pharma (NASDAQ:VRNA) Upgraded To Strong-Buy At Roth …

2 weeks from now

3 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th.The company reported ($0.56) earnings per share …

marketbeat.com

FAQs about Verona Pharma plc (NASDAQ:VRNA) Given Consensus Rating of Coupon?

Is Verona Pharma (vRNA) a good stock to buy?

Verona Pharma (NASDAQ:VRNA – Get Free Report) had its price target raised by investment analysts at Wells Fargo & Company from $64.00 to $74.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. ...

Is Verona Pharma a good buy?

Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Verona Pharma presently has an average rating of “Buy” and an average target price of $50.57. ...

How much does Verona Pharma stock cost?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Verona Pharma is $50.57, with a high forecast of $74.00 and a low forecast of $33.00. Should I buy or sell Verona Pharma stock right now? ...

Should you buy Verona Pharma plc American depositary share (vRNA)?

Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. ...

What is the price target for Verona Pharma (vRNA)?

The highest price target for VRNA is $74.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 14.23% from the current price of $44.27. Enter your email address to receive the latest news and analysts' ratings for Verona Pharma and its competitors. ...

What percentage of Verona Pharma stock are owned by insiders?

In the past three months, Verona Pharma insiders have sold 5,060.08% more of their company's stock than they have bought. Specifically, they have bought $188,928.00 in company stock and sold $9,748,833.00 in company stock. Only 4.80% of the stock of Verona Pharma is held by insiders. 85.88% of the stock of Verona Pharma is held by institutions. ...